North Carolina has contracts with a variety ofcompanies for the services of J.B.B. as an in-vestigator and/or consultant, including Amy-lin Pharmaceuticals, Bristol-Myers Squibb, EliLilly, GlaxoSmithKline, Hoffman-La Roche,Merck, Novo Nordisk, Pﬁzer, sanoﬁ-aventis,and Wyeth. D.J.D. has served as an advisor orconsultant within the past 12 months to Amy-lin Pharmaceuticals, Arena Pharmaceuticals,Arisaph Pharmaceuticals, Eli Lilly, Glaxo-SmithKline, Hoffman La Roche, Isis Pharma-ceuticals, Merck Research Laboratories,Metabolex, Novartis Pharmaceuticals, NovoNordisk, and Transition Pharmaceuticals.Neither D.J.D. nor his family members holdstock directly or indirectly in any of these com-panies. J.B.B. and D.J.D. had full access to theprimary data and led decisions on content.K.L.T., T.K., B.W., H.H., K.W., L.Z.S., andL.P. are employees and stockholders of Amy-lin Pharmaceuticals. M.T. is an employee andstockholder of Eli Lilly & Co